Raymond Furey - Sep 15, 2025 Form 4 Insider Report for RIGEL PHARMACEUTICALS INC (RIGL)

Role
EVP, GC, CCO & Corp Sec
Signature
/s/ Raymond Furey
Stock symbol
RIGL
Transactions as of
Sep 15, 2025
Transactions value $
$0
Form type
4
Date filed
9/17/2025, 04:26 PM
Previous filing
Mar 19, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Furey Raymond J. EVP, GC, CCO & Corp Sec RIGEL PHARMACEUTICALS, INC., 611 GATEWAY BLVD, SUITE 900, SOUTH SAN FRANCISCO /s/ Raymond Furey 2025-09-17 0001577899

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RIGL Employee Stock Option (right to buy) Award $0 +7.39K $0.00 7.39K Sep 15, 2025 Common Stock 7.39K $22.49 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Reporting Person was granted a stock option with a performance-based condition with respect to 7,394 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On September 15, 2025, it was determined that the performance metric had been met.
F2 The option was fully vested on September 15, 2025, the date the determination was made that the performance metric had been met.